Scarica l'app Stockscreener
4.41
0.00%
0.00
Precedente Chiudi:
$4.41
Aprire:
$4.47
Volume 24 ore:
1.01M
Relative Volume:
0.73
Capitalizzazione di mercato:
$285.32M
Reddito:
$500
Utile/perdita netta:
$-54.44M
Rapporto P/E:
-3.7828
EPS:
-1.1658
Flusso di cassa netto:
$-49.91M
1 W Prestazione:
+7.04%
1M Prestazione:
-9.45%
6M Prestazione:
-22.22%
1 anno Prestazione:
+59.21%
Intervallo 1D:
$4.255
$4.52
Intervallo di 1 settimana:
$4.07
$4.545
Portata 52W:
$2.29
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Nome
Immuneering Corp
Settore
Industria
Telefono
617-500-8080
Indirizzo
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.41 | 285.32M | 500 | -54.44M | -49.91M | -1.1658 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Iniziato | Leerink Partners | Outperform |
| 2024-12-13 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-15 | Reiterato | Needham | Buy |
| 2024-03-15 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Iniziato | Needham | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-04-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Iniziato | Mizuho | Neutral |
| 2023-02-03 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Iniziato | Chardan Capital Markets | Buy |
| 2022-04-01 | Iniziato | Oppenheimer | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Immuneering Corp Borsa (IMRX) Ultime notizie
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Buying: Brett Hall Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus
New CFO Andrew Gengos joins Immuneering (NASDAQ: IMRX) with equity grant - Stock Titan
Immuneering names Andrew Gengos as CFO - MSN
Immuneering names Andrew Gengos as chief financial officer - Investing.com
Immuneering names Andrew Gengos as chief financial officer By Investing.com - Investing.com Canada
IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up - Yahoo Finance
Immuneering Corporation Files Form 8-K with SEC Detailing Company Information as of June 11, 2026 - Minichart
Immuneering doses first patient in phase 3 pancreatic cancer trial - Investing.com
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - The Manila Times
Immuneering Corporation Initiates Pivotal Phase 3 MAPKeeper 301 Trial to Evaluate Atebimetinib in Combination with mGnP for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial tests atebimetinib combo, results expected mid-2028 - Stock Titan
Uprising in pancreatic space more than Revolution - BioWorld News
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Mizuho reiterates Immuneering stock rating after trial data update - Investing.com
Immuneering Corporation 8-K SEC Filing: Company Information, NASDAQ Listing, and Compliance Details (June 1, 2026) - Minichart
According to a document submitted to the U.S. Securities and Exchange Commission, as of April 24, 2026, biotechnology company Immuneering Corp observed a median overall survival of 17.3 months in the intent-to-treat population of its 320 mg dosage gro - Bitget
[8-K] Immuneering Corp Reports Material Event - Stock Titan
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Immuneering stock maintained at Outperform by Oppenheimer on survival data - Investing.com South Africa
Immuneering reports median survival data from pancreatic trial - Investing.com
Immuneering Corporation Reports Promising 17.3 Months Median Overall Survival in First-Line Pancreatic Cancer Trial with Atebimetinib - Quiver Quantitative
Pancreatic cancer drug combo shows 17.3-month survival in trial - Stock Titan
Immuneering Corp stock (US45255L1089): IMRX trades around 5.36 USD ahead of key June data - AD HOC NEWS
Immuneering Corporation (IMRX) Slides 2.2% as Pressure Mounts Near Key SupportBreakout Stock Alerts - The Legal Advocate
IMRX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentCFO Commentary Report - The Legal Advocate
IMRX Q1 2026 Earnings: Narrower Loss Exceeds Expectations as Pipeline Progress ContinuesPre-Announcement Alert - newsline.com
MEK inhibitor delivers 17.3-month OS for pancreatic cancer - BioWorld News
IMRX Jumps As Immuneering Extends Cash Runway And Trial Pipeline - StocksToTrade
Immuneering reports 17.3-month survival in pancreatic cancer trial - Investing.com
Immuneering stock jumps on pancreatic cancer trial data By Investing.com - Investing.com Nigeria
Immuneering stock jumps on pancreatic cancer trial data - Investing.com
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy - The Manila Times
Immuneering Corporation to Present Phase 2a Trial Results for Atebimetinib at ASCO Annual Meeting on June 1, 2026 - Quiver Quantitative
Pancreatic cancer trial of Immuneering drug hits 17.3-month median survival - Stock Titan
Immuneering Corp stock (US45255L1089): clinical updates keep biotech investors watching - AD HOC NEWS
Immuneering Corporation (IMRX) Stock: Jumps +3.89%, Approaching $5.33 2026-05-20Diamond Pattern - The Legal Advocate
Can Revolution’s 'miracle' pancreatic cancer drug be topped? Immuneering, Actuate say yes - BioSpace
Immuneering stock (US45255L1089): Insider buying puts the biotech back in focus - AD HOC NEWS
Immuneering Corporation Reports Q1 2026 Financial Results and Announces Positive Phase 2a Pancreatic Cancer Trial Data – Minichart - Minichart
Immuneering Corp Q1 2026 10-Q Report: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Immuneering Hikes on Q1 Figures - Baystreet.ca
Immuneering Corp Azioni (IMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):